Acute mental status changes and hyperchloremic metabolic acidosis with long-term topiramate therapy

被引:30
作者
Stowe, CD
Bolliger, T
James, LP
Haley, TM
Griebel, ML
Farrar, HC
机构
[1] Univ Arkansas Med Sci, Coll Pharm, Dept Pharm Practice, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Coll Med, Dept Pediat, Little Rock, AR 72205 USA
[3] Arkansas Childrens Hosp, Little Rock, AR 72202 USA
来源
PHARMACOTHERAPY | 2000年 / 20卷 / 01期
关键词
D O I
10.1592/phco.20.1.105.34662
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Mental status changes and metabolic acidosis may occur with topiramate therapy. These adverse events were reported during dosage titration and with high dosages of the drug. A 20-year-old man receiving topiramate, valproic acid, and phenytoin experienced acute-onset mental status changes with hyperchloremic metabolic acidosis. He had been receiving a modest dose of topiramate for 9 months. He was weaned off topiramate over 5 days, and his mental status returned to baseline within 48 hours of discontinuing the agent. This case illustrates the need for close evaluation of patients who experience acute-onset mental status changes during topiramate therapy.
引用
收藏
页码:105 / 109
页数:5
相关论文
共 11 条
[1]  
Jackson EK, 1996, GOODMAN GILMANS PHAR, P685
[2]   MARKEDLY INCREASED OMEGA-OXIDATION OF VALPROATE IN FULMINANT HEPATIC-FAILURE [J].
KUHARA, T ;
INOUE, Y ;
MATSUMOTO, M ;
SHINKA, T ;
MATSUMOTO, I ;
KAWAHARA, N ;
SAKURA, N .
EPILEPSIA, 1990, 31 (02) :214-217
[3]   EFFECTS OF POLYTHERAPY WITH PHENYTOIN, CARBAMAZEPINE, AND STIRIPENTOL ON FORMATION OF 4-ENE-VALPROATE, A HEPATOTOXIC METABOLITE OF VALPROIC ACID [J].
LEVY, RH ;
RETTENMEIER, AW ;
ANDERSON, GD ;
WILENSKY, AJ ;
FRIEL, PN ;
BAILLIE, TA ;
ACHEAMPONG, A ;
TOR, J ;
GUYOT, M ;
LOISEAU, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (03) :225-235
[4]   A pharmacological and clinical review on topiramate, a new antiepileptic drug [J].
Perucca, E .
PHARMACOLOGICAL RESEARCH, 1997, 35 (04) :241-256
[5]   Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy [J].
Rosenfeld, WE ;
Liao, S ;
Kramer, LD ;
Anderson, G ;
Palmer, M ;
Levy, RH ;
Nayak, RK .
EPILEPSIA, 1997, 38 (03) :324-333
[6]  
SCHEAR MJ, 1990, EPILEPSIA, V31, pA643
[7]   TOPIRAMATE - PRECLINICAL EVALUATION OF A STRUCTURALLY NOVEL ANTICONVULSANT [J].
SHANK, RP ;
GARDOCKI, JF ;
VAUGHT, JL ;
DAVIS, CB ;
SCHUPSKY, JJ ;
RAFFA, RB ;
DODGSON, SJ ;
NORTEY, SO ;
MARYANOFF, BE .
EPILEPSIA, 1994, 35 (02) :450-460
[8]   Safety of topiramate: Adverse events and relationships to dosing [J].
Shorvon, SD .
EPILEPSIA, 1996, 37 :S18-S22
[9]   Efficacy and safety of topiramate in refractory epilepsy: A long-term prospective trial [J].
Tartara, A ;
Sartori, I ;
Manni, R ;
Galimberti, CA ;
DiFazio, M ;
Perucca, E .
ITALIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1996, 17 (06) :429-432
[10]   SODIUM VALPROATE-INDUCED HYPERAMMONEMIA IN THE RAT - ROLE OF THE KIDNEY [J].
WARTER, JM ;
IMLER, M ;
MARESCAUX, C ;
CHABRIER, G ;
RUMBACH, L ;
MICHELETTI, G ;
KRIEGER, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1983, 87 (2-3) :177-182